Home › All Companies › BMRN › Annual Report

BIOMARIN PHARMACEUTICAL INC (BMRN) — Annual Report

AI-Powered SEC Filing Analysis

← All BMRN filings
Latest Annual Report Filed: 2026-02-26

Key Insights

  • BioMarin Pharmaceutical Inc. reported stable revenue and earnings performance for the 2025 fiscal year, with continued growth in its core product portfolio.
  • The company maintained its research and development spending, investing in its pipeline of experimental therapies targeting rare genetic disorders.
  • BioMarin's balance sheet remains healthy, with a strong cash position and manageable debt levels, providing financial flexibility for future investments.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-26. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for BIOMARIN PHARMACEUTICAL INC

Quarterly Report Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.